Literature DB >> 2034206

Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis.

.   

Abstract

The occurrence of tuberculosis among persons with human immunodeficiency virus (HIV) infection has prompted the development of guidelines for the management of those who may have both tuberculous and HIV infections (1). These guidelines include the recommendation that all persons who are known to be infected with HIV, or are at increased risk of HIV infection, receive a tuberculin skin test (Mantoux test with tuberculin units 5 [TU] of purified protein derivative [PPD]-tuberculin). Those persons who have at least a 5 mm reaction to PPD should be considered for 1 year of isoniazid preventive therapy, unless otherwise contraindicated.

Entities:  

Mesh:

Year:  1991        PMID: 2034206

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  17 in total

1.  An ounce of prevention - The new wave in HIV therapy.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1992-03

Review 2.  Medical care of the elderly in the nursing home.

Authors:  P Starer; L S Libow
Journal:  J Gen Intern Med       Date:  1992 May-Jun       Impact factor: 5.128

3.  Performance of antigens used in detecting delayed-type hypersensitivity in adolescents infected with the human immunodeficiency virus.

Authors:  A S Rogers; J H Ellenberg; S D Douglas; L Henry-Reid; L Peralta; C M Wilson
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 4.  Cost effectiveness of antituberculosis interventions.

Authors:  A Castelo; P A Mathiasi; R Iunes; A L Kritski; M Dalcolmo; F Fiuza de Melo; M Drummond
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

5.  CD4+ T cells from HIV-1 patients with impaired Th1 effector responses to Mycobacterium tuberculosis exhibit diminished histone and nucleoprotein signatures.

Authors:  Lillian Seu; James A Mobley; Paul A Goepfert
Journal:  Clin Immunol       Date:  2017-05-25       Impact factor: 3.969

6.  Incentives and accessibility: a pilot study to promote adherence to TB prophylaxis in a high-risk community.

Authors:  J Lorvick; S Thompson; B R Edlin; A H Kral; A R Lifson; J K Watters
Journal:  J Urban Health       Date:  1999-12       Impact factor: 3.671

Review 7.  New developments in tuberculosis and HIV infection: an opportunity for prevention.

Authors:  J R Curtis; T M Hooton; C M Nolan
Journal:  J Gen Intern Med       Date:  1994-05       Impact factor: 5.128

8.  Preventive medicine for HIV-infected patients: an analysis of isoniazid prophylaxis for tuberculin reactors and for anergic patients.

Authors:  D N Rose; C B Schechter; H S Sacks
Journal:  J Gen Intern Med       Date:  1992 Nov-Dec       Impact factor: 5.128

Review 9.  Current and potential treatment of tuberculosis.

Authors:  S Houston; A Fanning
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

10.  HIV infection and sputum-culture conversion in patients diagnosed with Mycobacterium tuberculosis: a population-based study.

Authors:  Muktar H Aliyu; Hamisu M Salihu; Raoul Ratard
Journal:  Wien Klin Wochenschr       Date:  2003-05-30       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.